Device Trial Radar · NCT07864415
High-Flow Tracheal Oxygen During Spontaneous Breathing Trial
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Dec 31, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Argentinian Intensive Care SocietyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out whether high-flow tracheal oxygen (HFTO) delivered at flows greater than 60 L/min can increase end-expiratory lung volume (EELV) in intubated patients during a spontaneous breathing trial (SBT). Weaning from mechanical ventilation can be difficult, especially in patients at higher risk of failure. During an SBT, losing positive end-expiratory pressure (PEEP) can cause the lungs to lose volume and make breathing harder by increasing the work of breathing (WOB). HFTO may help reduce the work of breathing, but previous studies using flows of 30-60 L/min did not consistently show an increase in EELV. Higher flows may create more airway pressure. Therefore, the main question this study is trying to answer is: In intubated patients during an SBT, does HFTO at flows greater than 60 L/min increase EELV? The hypothesis is that HFTO at flows above 60 L/min will increase EELV during the SBT.
Conditions
- Mechanical Ventilation Weaning
- Spontaneous Breathing Trial
- High Flow Oxygen Therapy
Interventions
T-piece, HFTO 50, washout, HFTO 70, washout, PSV.Device
Participants randomized to this Sequence receive the following conditions during a spontaneous breathing trial (SBT): T-piece (baseline) - 15 minutes High-flow tracheal oxygen (HFTO) at 50 L/min - 15 minutes Washout on T-piece - 15 minutes HFTO at 70 L/min - 15 minutes Washout on T-piece - 15 minutes Pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O - 15 minutes Throughout the sequence, end-expiratory lung impedance (EELI), work of breathing (esophageal pressure-derived parameters), respiratory rate, SpO₂, hemodynamic variables, dyspnea, and diaphragmatic thickening fraction (DTF) are measured. This is one of two randomized crossover sequences; all participants receive all conditions in the order assigned by randomization.
T-piece, HFTO 70, washout, HFTO 50, washout, PSV.Device
Participants randomized to this Sequence receive the following conditions during a spontaneous breathing trial (SBT): T-piece (baseline) - 15 minutes High-flow tracheal oxygen (HFTO) at 70 L/min - 15 minutes Washout on T-piece - 15 minutes HFTO at 50 L/min - 15 minutes Washout on T-piece - 15 minutes Pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O - 15 minutes Throughout the sequence, end-expiratory lung impedance (EELI), work of breathing (esophageal pressure-derived parameters: ΔPes, PTPes, PTPes-min), respiratory rate, SpO₂, hemodynamic variables, dyspnea, and diaphragmatic thickening fraction (DTF) are measured. This is one of two randomized crossover sequences; all participants receive all conditions in the order assigned by randomization.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in end-expiratory lung impedance (EELI) during spontaneous breathing trialTime frame: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Británico de Buenos Aires
Buenos Aires, Argentina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.